The APOBEC3A Knockout KYSE-30 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the human esophageal squamous cell carcinoma line KYSE-30, engineered with targeted disruption of the APOBEC3A gene. This loss-of-function model provides a genetically heterogeneous pool of cells carrying diverse CRISPR/Cas9-mediated disruptions, enabling robust studies of APOBEC3A-dependent phenotypes without clonal selection bias. The polyclonal format captures the complexity of APOBEC3A function across a wide spectrum of mutations, offering a versatile platform for functional genomics in epithelial cancer biology.
The KYSE-30 cell line was originally established from a poorly differentiated squamous cell carcinoma of the esophagus and serves as a well-characterized in vitro model for ESCC. These adherent human cells retain molecular features of primary tumors, including TP53 mutations and active interferon signaling pathways, making them a physiologically relevant substrate for investigating APOBEC3A-mediated mutagenesis in the esophageal cancer context. KYSE-30 cells thus provide a robust host background for studying the intersection of innate immunity and genomic instability.
APOBEC3A functions as an interferon-stimulated cytidine deaminase that catalyzes C-to-U editing in single-stranded DNA, a process governed by upstream activation through the type I interferon receptor (IFNAR)-JAK1/TYK2-STAT1/STAT2-IRF9 signaling axis. Upon induction, APOBEC3A deaminates cytidine residues within genomic ssDNA and viral genomes, generating uracil lesions that, when processed by uracil DNA glycosylase (UNG) and downstream base excision repair components, lead to double-strand breaks and somatic hypermutation. Key downstream targets include TP53 and PIK3CA, the latter being frequently mutated in ESCC. APOBEC3A thus directly couples innate immune signaling to replication-dependent mutagenesis and cancer genome evolution.
In the KYSE-30 esophageal carcinoma context, APOBEC3A is poised to contribute to the characteristic C-to-T and C-to-G mutation signatures observed in ESCC genomes. The polyclonal knockout population enables researchers to dissect the enzyme??s contribution to interferon-driven genomic instability without clonal artifacts. By comparing edited and unedited cells under pro-inflammatory stimuli, one can assess APOBEC3A-dependent DNA damage responses, replication stress, and cell-cycle perturbations, providing a direct link between innate immunity and somatic evolution in esophageal cancer. This model thus addresses the dual role of APOBEC3A in antiviral defense and cancer progression.
This polyclonal APOBEC3A knockout model is ideally suited for deaminase activity assays, C-to-T mutation sequencing, and ??-H2AX foci-based DNA damage quantification, enabling rigorous analysis of APOBEC3A catalytic function. Applications extend to exploring the interplay between interferon signaling and somatic mutagenesis, dissecting APOBEC3A-dependent mutational signatures in ESCC, and screening compounds that modulate cytidine deaminase activity for antiviral or anticancer purposes. Routine endpoints include RT-qPCR and Western blotting for expression validation, immunofluorescence for subcellular localization, and flow cytometry for cell cycle effects. For additional technical information or custom assay support, please contact Ascent Research.
